Lung Cancer

Retrospective Studies Confirm Survival Benefit of Stereotactic Body Radiotherapy in Early-Stage NSCLC

Stereotactic body radiation therapy is becoming more widely adopted for the treatment of early-stage non–small cell lung cancer (NSCLC). Along with its increasing uptake...

Prostate Cancer

Safety of Extreme Hypofractionation Reassuring in Intermediate-Risk Prostate Cancer

Giving patients larger fractions of radiation over shorter periods (ie, hypofractionation) is gaining ground in several types of cancers. This approach is attractive for patients’ convenience...

CNS Cancers

Stereotactic Radiosurgery Achieves Better Quality of Life and Improved Cognition Than Whole-Brain Radiotherapy

Two separate randomized trials presented at the 58th Annual Meeting of the American Society of Radiation Oncology (ASTRO) affirmed the value of stereotactic radiosurgery...


More Top Stories

Bruce D. Minsky, MD's, Meeting Highlights: An Expert Perspective

ASCO Presents First-Ever Congressional Leadership Award to Rep. Michael Burgess, MD

ASCO presented Representative Michael Burgess, MD (TX-26) with its first-ever ASCO Congressional Leadership Award on September 21 to recognize his steadfast work to support policies related to cancer research and treatment. This new, annual award honors a member of Congress who is a consistent...


Osimertinib Shows Activity in Pretreated EGFR Thr790Met–Positive Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Goss et al found that osimertinib produced a high response rate in EGFR tyrosine kinase inhibitor–pretreated EGFR Thr790Met (T790M)–positive advanced non–small cell lung cancer (NSCLC). Osimertinib is an EGFR tyrosine kinase...

Multiple Myeloma

Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study

Supportive Care

Prehabilitation and Rehabilitation May Improve Work-Related Outcomes in Cancer Survivors

In August 2016, the Healthcare Delivery Research Program of the Division of Cancer Control and Population Sciences at the National Cancer Institute convened a group of experts in a variety of fields to identify a research agenda for optimizing employment outcomes among cancer survivors. A core...

Jacques Galipeau, MD, FRCP(C), Brings Personalized Stem Cell Treatment to UW Carbone

An international leader in harnessing a patient’s own stem cells to fight cancer and autoimmune diseases joined the faculty of the University of Wisconsin (UW) Carbone Cancer Center on September 1. Jacques Galipeau, MD, FRCP(C), came from the Winship Cancer Center at Emory University, where he...

CDC Recommends Only Two HPV Shots for Younger Adolescents

The Centers for Disease Control and Prevention (CDC) have recommended that 11- to 12-year-olds receive 2 doses of human papillomavirus (HPV) vaccine at least 6 months apart rather than the previously recommended 3 doses to protect against cancers caused by HPV infections. Teens and young adults who ...

Issues in Oncology

Lia M. Halasz, MD, on Disparities in Radiotherapy Delivery

University of Michigan Cancer Center Names Four New Leaders

The University of Michigan (U-M) Comprehensive Cancer Center has appointed four new leaders to oversee the direction and operation of its research enterprise.

  • Pavan Reddy, MD, Deputy Director
  • Alnawaz Rehemtulla, PhD, Associate Director for Shared Resources
  • Anne Schott, MD, Associate Director...


KEYNOTE-045 Studying Pembrolizumab in Advanced Bladder Cancer Meets Primary Endpoint and Stops Early

Merck announced October 21, 2016, that the phase III KEYNOTE-045 trial investigating the use of pembrolizumab (Keytruda), the company’s anti–PD-1 (programmed cell death protein 1) therapy in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall ...

click me